Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-095634
Filing Date
2025-10-01
Accepted
2025-10-01 16:15:17
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10436
2 EXHIBIT I tm2527742d1_ex-1.htm EX-99.1 5846
  Complete submission text file 0001104659-25-095634.txt   18062
Mailing Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022
Business Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022 (212) 841-4100
INTEGRATED CORE STRATEGIES (US) LLC (Filed by) CIK: 0001319244 (see all company filings)

EIN.: 980330397 | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Subject) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90437 | Film No.: 251364803
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)